News

Researchers at Mount Sinai Investigate a Novel Class of Drugs for MPN Patients

Researchers in The Tisch Cancer Institute's Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients.

MPNRF Celebrates 1st Annual Founder's Day

The MPN Research Foundation is celebrating our first annual Founder's Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob's birthday, and we look forward to celebrating his legacy on this day for years to come.

Clinical Trial for AVID200 Doses First MF Patient

A TGF-Beta inhibitor - AVID 200 - is joining the race for new therapies for myeloproliferative neoplasms.

MPN Research Foundation's Patient Registry Featured in Cure Today

In an article published by CURE Magazine, Robyn M. Scherber, M.D., M.P.H, assistant professor of medicine in the Department of Hematology and Oncology at UT Health San Antonio MD Anderson Cancer Center, and co-author Michelle Woehrle, the executive director of the MPN Research Foundation sat down to discuss the newest findings from MPNRF's patient registry, myMPN.

Update on Promising MF Treatment, Momelotinib

Sierra Oncology is planning a new clinical trial for myelofibrosis patients called the MOMENTUM study.

MPNRF's Spring 2019 Newsletter has arrived!

Catch up on all the latest happenings in the global MPN community!

What Is This Rare Blood Cancer That Can Cause the Blood to Thicken?

Today on the CBS program, "The Doctors," Dr. Travis sits down with Matt, a polycythemia vera patient, and his physical Dr. Ellen Ritchie.

U.S. FDA Grants Priority Review for Fedratinib - New Drug Application in Myelofibrosis

In a press release published today, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review for Fedratinib.

It's Rare Disease day AND a MATCH day!

The MPN Research Foundation is doing our part to advocate for the MPN patient population. The needs of patients are first and foremost in our minds when we choose what researchers to support, have conversations with the FDA, and raise awareness about these rare blood cancers.

Exciting Announcement from MPNRF!

This fall, in collaboration with MPN Advocacy & Education Int'l, The Leukemia & Lymphoma Society and UT Health San Antonio MD Anderson Cancer Center, MPNRF will be holding an externally led patient-focused drug development (PFDD) meeting with the U.S. Food and Drug Administration (FDA).

Breaking news on ropeginterferon for PV patients

Click here to read the entire press release.

​Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors.

Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict transplantation outcomes. We retrospectively evaluated transplantation outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed the impact of molecular markers on outcomes based on a 72-gene next-generation sequencing panel and Mutation-Enhanced International Prognostic Scoring System 70+ v2.0 (MIPSS70+ v2.0).

"Primary myelofibrosis (PMF) can be treated with allogenic stem cell transplant (which can cure the disease or prolong survival) or with drug therapy, splenectomy, and radiation. Determining the appropriate time for a transplant is an important objective in tailoring treatment to the individual patient, and currently, the mutation- and karyotype-enhanced prognostic scoring system (MIPSS70 + version 2.0), a risk model for overall survival, is one tool used to do so. A recent study sought to develop a complementary, robust predictive model for patients whose disease will transform into acute myeloid leukemia, a complication that is associated with a poor prognosis."